JP2009515984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515984A5 JP2009515984A5 JP2008541312A JP2008541312A JP2009515984A5 JP 2009515984 A5 JP2009515984 A5 JP 2009515984A5 JP 2008541312 A JP2008541312 A JP 2008541312A JP 2008541312 A JP2008541312 A JP 2008541312A JP 2009515984 A5 JP2009515984 A5 JP 2009515984A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- aliphatic
- composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000001931 aliphatic group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 26
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000001118 alkylidene group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 2
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- -1 hydrogen compound Chemical class 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000001228 trophic effect Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 0 CC(**1)=Nc2c1c(S(N(*)*)(=O)=O)n[n]2 Chemical compound CC(**1)=Nc2c1c(S(N(*)*)(=O)=O)n[n]2 0.000 description 25
- FWGSHULJUPSFIP-UHFFFAOYSA-N C#[N]1(CS(c2n[nH]c3ncccc23)(=O)=O)CCOCC1 Chemical compound C#[N]1(CS(c2n[nH]c3ncccc23)(=O)=O)CCOCC1 FWGSHULJUPSFIP-UHFFFAOYSA-N 0.000 description 2
- KWNCEKCIPVVICF-UHFFFAOYSA-N CC(C)(C)c1ccc(CNS(c2n[nH]c3ncccc23)(=O)=O)cc1 Chemical compound CC(C)(C)c1ccc(CNS(c2n[nH]c3ncccc23)(=O)=O)cc1 KWNCEKCIPVVICF-UHFFFAOYSA-N 0.000 description 2
- OQKCWXTUMRCBKE-UHFFFAOYSA-N CC(CC1)CN1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CC1)CN1S(c1n[nH]c2ncccc12)(=O)=O OQKCWXTUMRCBKE-UHFFFAOYSA-N 0.000 description 2
- LWBPQZCTWMQDSF-UHFFFAOYSA-N CC(CCNS(c1n[nH]c2ncccc12)(=O)=O)Sc1ccccc1 Chemical compound CC(CCNS(c1n[nH]c2ncccc12)(=O)=O)Sc1ccccc1 LWBPQZCTWMQDSF-UHFFFAOYSA-N 0.000 description 2
- UDUOIFBLGVZAJN-UHFFFAOYSA-M CC([N-]C(CC1)CN1S(c1n[nH]c2ncccc12)(=O)=O)=O Chemical compound CC([N-]C(CC1)CN1S(c1n[nH]c2ncccc12)(=O)=O)=O UDUOIFBLGVZAJN-UHFFFAOYSA-M 0.000 description 2
- KZIIJKUTGCTPIS-UHFFFAOYSA-N CC(c(cc1)ccc1-c1ccccc1)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(c(cc1)ccc1-c1ccccc1)NS(c1n[nH]c2ncccc12)(=O)=O KZIIJKUTGCTPIS-UHFFFAOYSA-N 0.000 description 2
- ZLQPNYCJEVFYLO-HCCKASOXSA-N CC(c1cccnc1NN)S(N(CC1)C[C@@H]1NC(C)=O)(=O)=O Chemical compound CC(c1cccnc1NN)S(N(CC1)C[C@@H]1NC(C)=O)(=O)=O ZLQPNYCJEVFYLO-HCCKASOXSA-N 0.000 description 2
- FMAQCEKVSNRHSW-UHFFFAOYSA-N CC(c1cccnc1NN)S(NC(C)(C)Cc1ccc(C)cc1)(=O)=O Chemical compound CC(c1cccnc1NN)S(NC(C)(C)Cc1ccc(C)cc1)(=O)=O FMAQCEKVSNRHSW-UHFFFAOYSA-N 0.000 description 2
- FBYCEWHZTDKUDU-SEEMLRNQSA-N CCC([C@@]1(C)CC(CC)CC1)NS(C1=NNC2=NC=CCC12C)(=O)=O Chemical compound CCC([C@@]1(C)CC(CC)CC1)NS(C1=NNC2=NC=CCC12C)(=O)=O FBYCEWHZTDKUDU-SEEMLRNQSA-N 0.000 description 2
- FHQBXDQYWIINRX-UHFFFAOYSA-N CCCC(C(C)(C)N)O Chemical compound CCCC(C(C)(C)N)O FHQBXDQYWIINRX-UHFFFAOYSA-N 0.000 description 2
- LKYMCWQFGLPPIT-ZETCQYMHSA-N CC[C@@H](C(F)(F)F)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC[C@@H](C(F)(F)F)NS(c1n[nH]c2ncccc12)(=O)=O LKYMCWQFGLPPIT-ZETCQYMHSA-N 0.000 description 2
- CWRSZNINFSPSPD-QMMMGPOBSA-N CC[C@H](C)CNS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC[C@H](C)CNS(c1n[nH]c2ncccc12)(=O)=O CWRSZNINFSPSPD-QMMMGPOBSA-N 0.000 description 2
- DHZKEKQFRSWBML-UDJKBAMHSA-N CC[C@H](COCc1ccccc1)NS(/C(/c1cccnc1N)=N/C)(=O)=O Chemical compound CC[C@H](COCc1ccccc1)NS(/C(/c1cccnc1N)=N/C)(=O)=O DHZKEKQFRSWBML-UDJKBAMHSA-N 0.000 description 2
- OOYSJQPAQOSXBB-UHFFFAOYSA-N COc1c(C(CC2)CCN2S(c2n[nH]c3ncccc23)(=O)=O)cccc1 Chemical compound COc1c(C(CC2)CCN2S(c2n[nH]c3ncccc23)(=O)=O)cccc1 OOYSJQPAQOSXBB-UHFFFAOYSA-N 0.000 description 2
- HVZUVXJPRUFGNE-UHFFFAOYSA-N COc1cc(CNS(c2n[nH]c3ncccc23)(=O)=O)ccc1OCc1ccccc1 Chemical compound COc1cc(CNS(c2n[nH]c3ncccc23)(=O)=O)ccc1OCc1ccccc1 HVZUVXJPRUFGNE-UHFFFAOYSA-N 0.000 description 2
- XDGAYIBEGVTXDU-UHFFFAOYSA-N COc1ccc(C(Cc2ccccc2)NS(c2n[nH]c3ncccc23)(=O)=O)cc1OC Chemical compound COc1ccc(C(Cc2ccccc2)NS(c2n[nH]c3ncccc23)(=O)=O)cc1OC XDGAYIBEGVTXDU-UHFFFAOYSA-N 0.000 description 2
- HDFNMMDXOQONFW-UHFFFAOYSA-N CS(C(CC1)CN1S(c1n[nH]c2ncccc12)(=O)=O)(=O)=O Chemical compound CS(C(CC1)CN1S(c1n[nH]c2ncccc12)(=O)=O)(=O)=O HDFNMMDXOQONFW-UHFFFAOYSA-N 0.000 description 2
- AHCPEVAYECZZPF-PZORYLMUSA-N C[C@H](CCc(cc1OC)ccc1O)NS(C(C)c1cccnc1NN)(=O)=O Chemical compound C[C@H](CCc(cc1OC)ccc1O)NS(C(C)c1cccnc1NN)(=O)=O AHCPEVAYECZZPF-PZORYLMUSA-N 0.000 description 2
- RXXIQXKECBGHFE-HTRCEHHLSA-N C[C@H]([C@@H](CO)NS(c1n[nH]c2ncccc12)(=O)=O)O Chemical compound C[C@H]([C@@H](CO)NS(c1n[nH]c2ncccc12)(=O)=O)O RXXIQXKECBGHFE-HTRCEHHLSA-N 0.000 description 2
- IRJPYWOHKHWXKO-UHFFFAOYSA-N Cc(c(C)c1)cc2c1nc(CNS(c1n[nH]c3ncccc13)(=O)=O)[nH]2 Chemical compound Cc(c(C)c1)cc2c1nc(CNS(c1n[nH]c3ncccc13)(=O)=O)[nH]2 IRJPYWOHKHWXKO-UHFFFAOYSA-N 0.000 description 2
- HYIBXOKQIMIBHD-UHFFFAOYSA-N Cc1c(CNS(c2n[nH]c3ncccc23)(=O)=O)c(-c2ccccc2)n[o]1 Chemical compound Cc1c(CNS(c2n[nH]c3ncccc23)(=O)=O)c(-c2ccccc2)n[o]1 HYIBXOKQIMIBHD-UHFFFAOYSA-N 0.000 description 2
- XTIHOCRTBVPSIW-UHFFFAOYSA-N Cc1ccc(C(c(cc2)ccc2O)NS(c2n[nH]c3ncccc23)=O)cc1 Chemical compound Cc1ccc(C(c(cc2)ccc2O)NS(c2n[nH]c3ncccc23)=O)cc1 XTIHOCRTBVPSIW-UHFFFAOYSA-N 0.000 description 2
- DFUXYVRGRNRRID-UHFFFAOYSA-N N#CC1CCC(CNS(c2n[nH]c3ncccc23)(=O)=O)CC1 Chemical compound N#CC1CCC(CNS(c2n[nH]c3ncccc23)(=O)=O)CC1 DFUXYVRGRNRRID-UHFFFAOYSA-N 0.000 description 2
- UDQCRUSSQAXPJY-UHFFFAOYSA-N NC(Cc1c[nH]c2ccccc12)CO Chemical compound NC(Cc1c[nH]c2ccccc12)CO UDQCRUSSQAXPJY-UHFFFAOYSA-N 0.000 description 2
- FHKJKGRKQLAKRG-UHFFFAOYSA-N Nc1ncccc1C(S(N1CCCC1)(=O)=O)=N Chemical compound Nc1ncccc1C(S(N1CCCC1)(=O)=O)=N FHKJKGRKQLAKRG-UHFFFAOYSA-N 0.000 description 2
- BPTLPWBUZKXRHI-UHFFFAOYSA-N Nc1ncccc1C(S(NCC(C(F)(F)F)c1ccc[nH]1)(=O)=O)=N Chemical compound Nc1ncccc1C(S(NCC(C(F)(F)F)c1ccc[nH]1)(=O)=O)=N BPTLPWBUZKXRHI-UHFFFAOYSA-N 0.000 description 2
- DIGCZWAHECIZCA-UHFFFAOYSA-N Nc1ncccc1C(S=O)=N Chemical compound Nc1ncccc1C(S=O)=N DIGCZWAHECIZCA-UHFFFAOYSA-N 0.000 description 2
- PYZMZQURGLDKPZ-BJIRRVCCSA-N O=CC(c1n[nH]c2ncccc12)S(N[C@H]1C=CCCC1)=O Chemical compound O=CC(c1n[nH]c2ncccc12)S(N[C@H]1C=CCCC1)=O PYZMZQURGLDKPZ-BJIRRVCCSA-N 0.000 description 2
- NVRUKSWIBSLVQB-UHFFFAOYSA-N O=S(CNCCc1cnc[nH]1)(c1n[nH]c2ncccc12)=O Chemical compound O=S(CNCCc1cnc[nH]1)(c1n[nH]c2ncccc12)=O NVRUKSWIBSLVQB-UHFFFAOYSA-N 0.000 description 2
- RHBZCMWIKQYNBR-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(N(CC1)CCC1N1CCCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N(CC1)CCC1N1CCCC1)=O RHBZCMWIKQYNBR-UHFFFAOYSA-N 0.000 description 2
- ZQLVMRONTKKXKK-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NC(C(F)(F)F)C1=CCCC=C1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NC(C(F)(F)F)C1=CCCC=C1)=O ZQLVMRONTKKXKK-UHFFFAOYSA-N 0.000 description 2
- NTEDKSJHXQSDCD-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NC1(C2)C(C3)CC2CC3C1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NC1(C2)C(C3)CC2CC3C1)=O NTEDKSJHXQSDCD-UHFFFAOYSA-N 0.000 description 2
- QBXIJYCDPSRLKR-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCC(C(c1ccccc1)c1ccccc1)F)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCC(C(c1ccccc1)c1ccccc1)F)=O QBXIJYCDPSRLKR-UHFFFAOYSA-N 0.000 description 2
- GPBJIHFQAGIMCC-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCSc(cc1)ccc1F)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCSc(cc1)ccc1F)=O GPBJIHFQAGIMCC-UHFFFAOYSA-N 0.000 description 2
- AKTWRXUAFLRJNX-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCc1cc(F)cc(F)c1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCc1cc(F)cc(F)c1)=O AKTWRXUAFLRJNX-UHFFFAOYSA-N 0.000 description 2
- RJCURXKTKKECHL-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCc1ccc(C(F)(F)F)cc1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCc1ccc(C(F)(F)F)cc1)=O RJCURXKTKKECHL-UHFFFAOYSA-N 0.000 description 2
- ODFGTVPFTQBMBZ-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc(cc1)ccc1Oc(cc1)ccc1F)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc(cc1)ccc1Oc(cc1)ccc1F)=O ODFGTVPFTQBMBZ-UHFFFAOYSA-N 0.000 description 2
- BFTITQXLPHRWQB-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc1c[s]c(-c2ccc[s]2)n1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc1c[s]c(-c2ccc[s]2)n1)=O BFTITQXLPHRWQB-UHFFFAOYSA-N 0.000 description 2
- RHRUTNLHFKLHQJ-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)=O Chemical compound O=S(c1n[nH]c2ncccc12)=O RHRUTNLHFKLHQJ-UHFFFAOYSA-N 0.000 description 2
- ASQOGVMMUUDJPS-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)NC1c2ccccc2CC1Cl Chemical compound O=S(c1n[nH]c2ncccc12)NC1c2ccccc2CC1Cl ASQOGVMMUUDJPS-UHFFFAOYSA-N 0.000 description 2
- KZMNOHWGEZGJFO-YYQWEOLTSA-N OC([C@H]([C@]12C(C3)C1C2)N3S(c1n[nH]c2ncccc12)(=O)=O)=O Chemical compound OC([C@H]([C@]12C(C3)C1C2)N3S(c1n[nH]c2ncccc12)(=O)=O)=O KZMNOHWGEZGJFO-YYQWEOLTSA-N 0.000 description 2
- VLFZHFYSKCPHOM-UHFFFAOYSA-N OCC(C1CC2CC1)C2NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound OCC(C1CC2CC1)C2NS(c1n[nH]c2ncccc12)(=O)=O VLFZHFYSKCPHOM-UHFFFAOYSA-N 0.000 description 2
- POUYCAKDXQKVJO-UHFFFAOYSA-N OCC(CC(CC1)c2ccccc2)C1NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound OCC(CC(CC1)c2ccccc2)C1NS(c1n[nH]c2ncccc12)(=O)=O POUYCAKDXQKVJO-UHFFFAOYSA-N 0.000 description 2
- ONFSYYWMWRUUPV-UHFFFAOYSA-N OCC(CC1CCCCC1)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound OCC(CC1CCCCC1)NS(c1n[nH]c2ncccc12)(=O)=O ONFSYYWMWRUUPV-UHFFFAOYSA-N 0.000 description 2
- ODHFSUQYGIVTGC-ONGXEEELSA-N OC[C@H](CCCC1)[C@H]1NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound OC[C@H](CCCC1)[C@H]1NS(c1n[nH]c2ncccc12)(=O)=O ODHFSUQYGIVTGC-ONGXEEELSA-N 0.000 description 2
- DETZLELRFGGBPZ-UHFFFAOYSA-N C=[S](c1n[nH]c2ncccc12)(N(CC1)CCC1(c(cc1)ccc1F)O)(=O)=O Chemical compound C=[S](c1n[nH]c2ncccc12)(N(CC1)CCC1(c(cc1)ccc1F)O)(=O)=O DETZLELRFGGBPZ-UHFFFAOYSA-N 0.000 description 1
- BGNLXETYTAAURD-UHFFFAOYSA-N CC(C)(C)C(CC1)CCC1N Chemical compound CC(C)(C)C(CC1)CCC1N BGNLXETYTAAURD-UHFFFAOYSA-N 0.000 description 1
- WMJWFKTWJOPCHU-UHFFFAOYSA-N CC(C)(C)CC(C)(C)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(C)(C)CC(C)(C)NS(c1n[nH]c2ncccc12)(=O)=O WMJWFKTWJOPCHU-UHFFFAOYSA-N 0.000 description 1
- QCFGZWQAQMOUDS-UHFFFAOYSA-N CC(C)(C)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(C)(C)NS(c1n[nH]c2ncccc12)(=O)=O QCFGZWQAQMOUDS-UHFFFAOYSA-N 0.000 description 1
- ACWKGWXBEOOZBP-UHFFFAOYSA-N CC(C)(C1)CC(C)(CNS(c2n[nH]c3ncccc23)(=O)=O)CC1O Chemical compound CC(C)(C1)CC(C)(CNS(c2n[nH]c3ncccc23)(=O)=O)CC1O ACWKGWXBEOOZBP-UHFFFAOYSA-N 0.000 description 1
- OOGQDLFTEKMAGJ-UHFFFAOYSA-N CC(C)C(C(C)C)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(C)C(C(C)C)NS(c1n[nH]c2ncccc12)(=O)=O OOGQDLFTEKMAGJ-UHFFFAOYSA-N 0.000 description 1
- AGQZXIYIDLYMFF-UHFFFAOYSA-N CC(C)c1cc(-c2ccccc2)n[nH]1 Chemical compound CC(C)c1cc(-c2ccccc2)n[nH]1 AGQZXIYIDLYMFF-UHFFFAOYSA-N 0.000 description 1
- RVISOWROPPCWIN-UHFFFAOYSA-N CC(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O RVISOWROPPCWIN-UHFFFAOYSA-N 0.000 description 1
- VZSLZUDXEAPLEL-UHFFFAOYSA-N CC(CCC1)CN1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CCC1)CN1S(c1n[nH]c2ncccc12)(=O)=O VZSLZUDXEAPLEL-UHFFFAOYSA-N 0.000 description 1
- QYZHILGPXWODHI-UHFFFAOYSA-N CC(CCC1)N1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CCC1)N1S(c1n[nH]c2ncccc12)(=O)=O QYZHILGPXWODHI-UHFFFAOYSA-N 0.000 description 1
- XYCAYURERXFPFG-UHFFFAOYSA-N CC(CCC1C)N1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CCC1C)N1S(c1n[nH]c2ncccc12)(=O)=O XYCAYURERXFPFG-UHFFFAOYSA-N 0.000 description 1
- HPCIQYOUMGSASX-UHFFFAOYSA-N CC(CCCC1)N1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CCCC1)N1S(c1n[nH]c2ncccc12)(=O)=O HPCIQYOUMGSASX-UHFFFAOYSA-N 0.000 description 1
- PTKVQEISAHZHMF-UHFFFAOYSA-N CC(CO)(CO)NS(Cc1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CO)(CO)NS(Cc1n[nH]c2ncccc12)(=O)=O PTKVQEISAHZHMF-UHFFFAOYSA-N 0.000 description 1
- PYAUPOWNDXXWAG-UHFFFAOYSA-N CC(COC)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(COC)NS(c1n[nH]c2ncccc12)(=O)=O PYAUPOWNDXXWAG-UHFFFAOYSA-N 0.000 description 1
- ZKUSXXDQRMCWBO-UHFFFAOYSA-N CC1C=CC(Sc2c(CNS(C(c3cccnc3N)=N)(=O)=O)cccc2)=C(CO)C1 Chemical compound CC1C=CC(Sc2c(CNS(C(c3cccnc3N)=N)(=O)=O)cccc2)=C(CO)C1 ZKUSXXDQRMCWBO-UHFFFAOYSA-N 0.000 description 1
- QIWYJXQYFKNMGB-UHFFFAOYSA-N CCC(CC)(C#C)NS(C(c1cccnc1N)=N)(=O)=O Chemical compound CCC(CC)(C#C)NS(C(c1cccnc1N)=N)(=O)=O QIWYJXQYFKNMGB-UHFFFAOYSA-N 0.000 description 1
- YIDRKEOGDSLZHH-UHFFFAOYSA-N CCC(Cc1cc(O)c(C)cc1)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CCC(Cc1cc(O)c(C)cc1)NS(c1n[nH]c2ncccc12)(=O)=O YIDRKEOGDSLZHH-UHFFFAOYSA-N 0.000 description 1
- QWADQNPBBYDWAV-UHFFFAOYSA-N CCCC(C1)NN=C1c1ccccc1 Chemical compound CCCC(C1)NN=C1c1ccccc1 QWADQNPBBYDWAV-UHFFFAOYSA-N 0.000 description 1
- YAYPGXWVKQPKIE-UHFFFAOYSA-N COc1cccc(OC)c1CNS(c1n[nH]c2ncccc12)(=O)=O Chemical compound COc1cccc(OC)c1CNS(c1n[nH]c2ncccc12)(=O)=O YAYPGXWVKQPKIE-UHFFFAOYSA-N 0.000 description 1
- UFEPUBHGHDYXNX-UHFFFAOYSA-N CS(c1n[nH]c2ncccc12)(N(CC1)CCC1C(N)=O)=O Chemical compound CS(c1n[nH]c2ncccc12)(N(CC1)CCC1C(N)=O)=O UFEPUBHGHDYXNX-UHFFFAOYSA-N 0.000 description 1
- FDPOELDPZFVLNE-UHFFFAOYSA-N CS(c1n[nH]c2ncccc12)(NCc(cc(cc1)Br)c1F)(O)=O Chemical compound CS(c1n[nH]c2ncccc12)(NCc(cc(cc1)Br)c1F)(O)=O FDPOELDPZFVLNE-UHFFFAOYSA-N 0.000 description 1
- DOBDRCXIWNUOKU-MRVPVSSYSA-O CSCC[C@H](CO)NS(C(c1cccnc1N)=[NH2+])(=O)=O Chemical compound CSCC[C@H](CO)NS(C(c1cccnc1N)=[NH2+])(=O)=O DOBDRCXIWNUOKU-MRVPVSSYSA-O 0.000 description 1
- NGKPUEACPWTPIJ-DXMXGDFPSA-N C[C@H]1C2(C)C3(C)[C@@H]1C[C@H]3C[C@H]2CNS(c1n[nH]c2ncccc12)(=O)=O Chemical compound C[C@H]1C2(C)C3(C)[C@@H]1C[C@H]3C[C@H]2CNS(c1n[nH]c2ncccc12)(=O)=O NGKPUEACPWTPIJ-DXMXGDFPSA-N 0.000 description 1
- GHTVAOBQFFQEOL-UHFFFAOYSA-N Cc1c(CN[S](c2n[nH]c3ncccc23)(=C)(=O)=O)c(Cl)cc(Cl)c1 Chemical compound Cc1c(CN[S](c2n[nH]c3ncccc23)(=C)(=O)=O)c(Cl)cc(Cl)c1 GHTVAOBQFFQEOL-UHFFFAOYSA-N 0.000 description 1
- QLTKTNZOICIYRL-UHFFFAOYSA-N Cc1cc(C)c(CSCCN)c(C)c1 Chemical compound Cc1cc(C)c(CSCCN)c(C)c1 QLTKTNZOICIYRL-UHFFFAOYSA-N 0.000 description 1
- FIJALLHHIBPLOL-UHFFFAOYSA-N Cc1cc(C)c(CSCCNS(c2n[nH]c3ncccc23)(=O)=O)c(C)c1 Chemical compound Cc1cc(C)c(CSCCNS(c2n[nH]c3ncccc23)(=O)=O)c(C)c1 FIJALLHHIBPLOL-UHFFFAOYSA-N 0.000 description 1
- WENPUFXCRFZVJJ-UHFFFAOYSA-N Cc1cc(NS(c(c2c3)n[nH]c2ncc3-c2cccnc2)(=O)=O)ccc1 Chemical compound Cc1cc(NS(c(c2c3)n[nH]c2ncc3-c2cccnc2)(=O)=O)ccc1 WENPUFXCRFZVJJ-UHFFFAOYSA-N 0.000 description 1
- FBTCGNXBBSIYSK-UHFFFAOYSA-N Cc1cc(NS(c(c2c3)n[nH]c2ncc3Br)(=O)=O)ccc1 Chemical compound Cc1cc(NS(c(c2c3)n[nH]c2ncc3Br)(=O)=O)ccc1 FBTCGNXBBSIYSK-UHFFFAOYSA-N 0.000 description 1
- MBWMNXXIVSSSGL-UHFFFAOYSA-N Cc1nc(-c2ccc(CNS(c3n[nH]c4ncccc34)=O)[s]2)c[s]1 Chemical compound Cc1nc(-c2ccc(CNS(c3n[nH]c4ncccc34)=O)[s]2)c[s]1 MBWMNXXIVSSSGL-UHFFFAOYSA-N 0.000 description 1
- LDZYRENCLPUXAX-UHFFFAOYSA-N Cc1nc(cccc2)c2[nH]1 Chemical compound Cc1nc(cccc2)c2[nH]1 LDZYRENCLPUXAX-UHFFFAOYSA-N 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N Cc1nnc[nH]1 Chemical compound Cc1nnc[nH]1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
- RQSCFNPNNLWQBJ-UHFFFAOYSA-N Cc1nnc[s]1 Chemical compound Cc1nnc[s]1 RQSCFNPNNLWQBJ-UHFFFAOYSA-N 0.000 description 1
- NYPBKJURFMHVEW-UHFFFAOYSA-N NC(C(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O)=O Chemical compound NC(C(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O)=O NYPBKJURFMHVEW-UHFFFAOYSA-N 0.000 description 1
- ZGGWCNZTBGCNNR-QMMMGPOBSA-N NC([C@H](CCC1)N1S(C(c1cccnc1N)=N)(=O)=O)=O Chemical compound NC([C@H](CCC1)N1S(C(c1cccnc1N)=N)(=O)=O)=O ZGGWCNZTBGCNNR-QMMMGPOBSA-N 0.000 description 1
- CRPPAJJSPLRCNK-UHFFFAOYSA-O Nc1ncccc1C(S(N(CC1)CCC1(c1ccccc1)O)(=O)=O)=[NH2+] Chemical compound Nc1ncccc1C(S(N(CC1)CCC1(c1ccccc1)O)(=O)=O)=[NH2+] CRPPAJJSPLRCNK-UHFFFAOYSA-O 0.000 description 1
- JITGQDHFEOCGMG-UHFFFAOYSA-O Nc1ncccc1C(S(N1CC(Cc2ccccc2)CC1)(=O)=O)=[NH2+] Chemical compound Nc1ncccc1C(S(N1CC(Cc2ccccc2)CC1)(=O)=O)=[NH2+] JITGQDHFEOCGMG-UHFFFAOYSA-O 0.000 description 1
- LGBVVYDICZEIRP-UHFFFAOYSA-N Nc1ncccc1C(S(NCCc(c(Cl)ccc1)c1Cl)(=O)=O)=N Chemical compound Nc1ncccc1C(S(NCCc(c(Cl)ccc1)c1Cl)(=O)=O)=N LGBVVYDICZEIRP-UHFFFAOYSA-N 0.000 description 1
- IZSMOXMQHIQEQD-UHFFFAOYSA-O Nc1ncccc1C(S(NCc(cc1)ccc1-c1c[s]nn1)(=O)=O)=[NH2+] Chemical compound Nc1ncccc1C(S(NCc(cc1)ccc1-c1c[s]nn1)(=O)=O)=[NH2+] IZSMOXMQHIQEQD-UHFFFAOYSA-O 0.000 description 1
- IWDLTHCDCQKTHA-UHFFFAOYSA-N Nc1ncccc1C(S(NCc1c[o]cc1)(=O)=O)=N Chemical compound Nc1ncccc1C(S(NCc1c[o]cc1)(=O)=O)=N IWDLTHCDCQKTHA-UHFFFAOYSA-N 0.000 description 1
- HGBSCHYMQGBFNG-UHFFFAOYSA-N O=C(Cc(c1c2)n[nH]c1ncc2Br)S(Nc(cc(cc1)N2CCCC2)c1F)=O Chemical compound O=C(Cc(c1c2)n[nH]c1ncc2Br)S(Nc(cc(cc1)N2CCCC2)c1F)=O HGBSCHYMQGBFNG-UHFFFAOYSA-N 0.000 description 1
- PBIZEUZJQKXYMI-UHFFFAOYSA-N O=S(Cc1n[nH]c2ncccc12)(N1CCCCC1)=O Chemical compound O=S(Cc1n[nH]c2ncccc12)(N1CCCCC1)=O PBIZEUZJQKXYMI-UHFFFAOYSA-N 0.000 description 1
- OWHHWYIZBYOREG-UHFFFAOYSA-N O=S(c(c1c2)n[nH]c1ncc2-c1cnccc1)(NCc1cccc(F)c1F)=O Chemical compound O=S(c(c1c2)n[nH]c1ncc2-c1cnccc1)(NCc1cccc(F)c1F)=O OWHHWYIZBYOREG-UHFFFAOYSA-N 0.000 description 1
- VMPHITSIVROZOJ-UHFFFAOYSA-N O=S(c(c1c2)n[nH]c1ncc2-c1cnccc1)(Nc1ccccc1)=O Chemical compound O=S(c(c1c2)n[nH]c1ncc2-c1cnccc1)(Nc1ccccc1)=O VMPHITSIVROZOJ-UHFFFAOYSA-N 0.000 description 1
- RZEIRDFEZVONAS-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(N(CCC1)C1c1cccnc1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N(CCC1)C1c1cccnc1)=O RZEIRDFEZVONAS-UHFFFAOYSA-N 0.000 description 1
- UZYHRBGNDXIGOO-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(N(CCCC1)C1c1cccnc1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N(CCCC1)C1c1cccnc1)=O UZYHRBGNDXIGOO-UHFFFAOYSA-N 0.000 description 1
- WVVTYLCXXSVMKW-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(N1CC(Cc2ccccc2)CC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N1CC(Cc2ccccc2)CC1)=O WVVTYLCXXSVMKW-UHFFFAOYSA-N 0.000 description 1
- PDYNVUZAPLLGFC-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(N1CCCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N1CCCC1)=O PDYNVUZAPLLGFC-UHFFFAOYSA-N 0.000 description 1
- NCHJJCOSANPWCD-LBPRGKRZSA-N O=S(c1n[nH]c2ncccc12)(N1[C@H](CN2CCCC2)CCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N1[C@H](CN2CCCC2)CCC1)=O NCHJJCOSANPWCD-LBPRGKRZSA-N 0.000 description 1
- WQUONYBNJSESNC-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCC1=CCCCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCC1=CCCCC1)=O WQUONYBNJSESNC-UHFFFAOYSA-N 0.000 description 1
- QZYZIJINMKSVSH-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCSCc(c(F)ccc1)c1Cl)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCSCc(c(F)ccc1)c1Cl)=O QZYZIJINMKSVSH-UHFFFAOYSA-N 0.000 description 1
- BKJFFUUKALQKBS-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCSc1c(cccc2)c2nc(C(F)(F)F)c1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCSc1c(cccc2)c2nc(C(F)(F)F)c1)=O BKJFFUUKALQKBS-UHFFFAOYSA-N 0.000 description 1
- KNRUAELJCWZTAQ-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCc(cc1Cl)ccc1Cl)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCc(cc1Cl)ccc1Cl)=O KNRUAELJCWZTAQ-UHFFFAOYSA-N 0.000 description 1
- QXHWCWZKJOQDPJ-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc(cc(cc1)Br)c1F)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc(cc(cc1)Br)c1F)=O QXHWCWZKJOQDPJ-UHFFFAOYSA-N 0.000 description 1
- PEDNYVOMNQHVCU-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc(cc1)ccc1-c1c[s]nn1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc(cc1)ccc1-c1c[s]nn1)=O PEDNYVOMNQHVCU-UHFFFAOYSA-N 0.000 description 1
- LVFQACLHBNQXIK-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc(cc1C(F)(F)F)ccc1Cl)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc(cc1C(F)(F)F)ccc1Cl)=O LVFQACLHBNQXIK-UHFFFAOYSA-N 0.000 description 1
- BLHFNDRRPWWIKZ-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc1c[o]cc1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc1c[o]cc1)=O BLHFNDRRPWWIKZ-UHFFFAOYSA-N 0.000 description 1
- MGEOENLEVFDWNN-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc1cc(F)cc2c1OCOC2)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc1cc(F)cc2c1OCOC2)=O MGEOENLEVFDWNN-UHFFFAOYSA-N 0.000 description 1
- DZASZHHRGFEODA-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc1cccc(F)c1F)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc1cccc(F)c1F)=O DZASZHHRGFEODA-UHFFFAOYSA-N 0.000 description 1
- XHBUZUUZQPEKAQ-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCc1cccc(OC(F)(F)F)c1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCc1cccc(OC(F)(F)F)c1)=O XHBUZUUZQPEKAQ-UHFFFAOYSA-N 0.000 description 1
- FSTFQBBSKFGDFF-UHFFFAOYSA-N OC(CC1)CN1S(c1n[nH]c2ncccc12)=O Chemical compound OC(CC1)CN1S(c1n[nH]c2ncccc12)=O FSTFQBBSKFGDFF-UHFFFAOYSA-N 0.000 description 1
- BHVWZCJYLSOEKI-UHFFFAOYSA-N OCC(c1cc(Cl)cc(Cl)c1)NS(C(c1n[nH]c2ncccc12)=O)=O Chemical compound OCC(c1cc(Cl)cc(Cl)c1)NS(C(c1n[nH]c2ncccc12)=O)=O BHVWZCJYLSOEKI-UHFFFAOYSA-N 0.000 description 1
- SVNQSKDORBBTHP-UHFFFAOYSA-N OCC(c1cc(Cl)cc(Cl)c1)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound OCC(c1cc(Cl)cc(Cl)c1)NS(c1n[nH]c2ncccc12)(=O)=O SVNQSKDORBBTHP-UHFFFAOYSA-N 0.000 description 1
- RITHGDGEMKOMRB-UHFFFAOYSA-N OCCC(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound OCCC(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O RITHGDGEMKOMRB-UHFFFAOYSA-N 0.000 description 1
- BXPLHJUAHUABQP-MSOLQXFVSA-N O[C@H]([C@@H](c1ccccc1)NS(c1n[nH]c2ncccc12)(=O)=O)c1ccccc1 Chemical compound O[C@H]([C@@H](c1ccccc1)NS(c1n[nH]c2ncccc12)(=O)=O)c1ccccc1 BXPLHJUAHUABQP-MSOLQXFVSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73710505P | 2005-11-15 | 2005-11-15 | |
| PCT/US2006/044361 WO2007059219A1 (en) | 2005-11-15 | 2006-11-15 | Azaindazoles useful as inhibitors of kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515984A JP2009515984A (ja) | 2009-04-16 |
| JP2009515984A5 true JP2009515984A5 (https=) | 2010-01-07 |
Family
ID=37860677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541312A Pending JP2009515984A (ja) | 2005-11-15 | 2006-11-15 | キナーゼ阻害剤として有用なアザインダゾール |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8017781B2 (https=) |
| EP (2) | EP1948657A1 (https=) |
| JP (1) | JP2009515984A (https=) |
| CN (1) | CN101365700A (https=) |
| AU (1) | AU2006315436A1 (https=) |
| CA (1) | CA2628179A1 (https=) |
| WO (1) | WO2007059219A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553639B2 (en) * | 2006-01-31 | 2009-06-30 | Elan Pharma International Limited | Alpha-synuclein kinase |
| CN101790532B (zh) * | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法 |
| CA2696288A1 (en) | 2007-08-15 | 2009-02-19 | Schering Corporation | 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11.beta.-hydroxysteroid dehydrogenase type-1 |
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| EP2247748A2 (en) * | 2008-02-13 | 2010-11-10 | Elan Pharma International Limited | Alpha-synuclein kinase |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| RS59144B1 (sr) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitori replikacije virusa influence |
| HRP20181272T1 (hr) | 2013-11-13 | 2018-10-05 | Vertex Pharmaceuticals Incorporated | Postupci priprave inhibitora replikacije virusa influence |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤 |
| US10590077B2 (en) * | 2016-09-20 | 2020-03-17 | Glaxosmithkline Intellectual Property Development Limited | TRPV4 antagonists |
| CN116687951B (zh) * | 2023-06-06 | 2026-01-02 | 河北渤腾医药技术有限公司 | 一种plk1的干扰rna及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420297A (en) * | 1990-10-24 | 1995-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having substance P antagonistic activity |
| GB9113219D0 (en) | 1991-06-19 | 1991-08-07 | Fujisawa Pharmaceutical Co | Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same |
| US5654400A (en) * | 1991-10-04 | 1997-08-05 | Fujisawa Pharmaceutical Co., Ltd. | Process for making peptide compounds having tachykinin antagonistic activity |
| JP3485198B2 (ja) * | 1993-11-10 | 2004-01-13 | 富士写真フイルム株式会社 | ヒドラジン化合物及び該化合物を含むハロゲン化銀写真感光材料 |
| PL181323B1 (pl) | 1994-02-18 | 2001-07-31 | Boehringer Ingelheim Pharma | 2-heteroarylo-5,11-dihydro-6H-dipirydo[3,2-b:2’,3'-e][1,4] diazepinyi ich zastosowanie w zapobieganiu i leczeniu zakazen HIV PL PL PL |
| GB9412719D0 (en) | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
| JPH11501289A (ja) | 1994-12-02 | 1999-02-02 | 藤沢薬品工業株式会社 | Ｎｏ介在疾患の予防および／または治療のためのペプチド化合物 |
| US5837704A (en) * | 1995-02-17 | 1998-11-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-heteroaryl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-E! 1,4!diazepines and their use in the prevention or treatment of HIV infection |
| US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| US6537999B2 (en) * | 1996-06-06 | 2003-03-25 | Duquesne University Of The Holy Ghost | Pyrimidine derivatives and methods of making and using these derivatives |
| JP4028607B2 (ja) | 1996-07-24 | 2007-12-26 | 富山化学工業株式会社 | 新規なセファロスポリン誘導体またはその塩 |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6025366A (en) * | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EP1071423A1 (en) | 1998-04-02 | 2001-01-31 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CA2325995A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6110931A (en) * | 1998-04-02 | 2000-08-29 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CA2342251A1 (en) * | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| US6319660B1 (en) * | 1998-12-28 | 2001-11-20 | Eastman Kodak Company | Color photographic element containing speed improving compound |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| CO5170498A1 (es) * | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
| US6309811B2 (en) * | 1999-07-21 | 2001-10-30 | Eastman Kodak Company | Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler |
| EP1252154A1 (en) * | 2000-02-04 | 2002-10-30 | Pfizer Products Inc. | Heterocyclic amide derivatives |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| GB0106661D0 (en) | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (en) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| GB0218800D0 (en) | 2002-08-13 | 2002-09-18 | Celltech R&D Ltd | Chemical compounds |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| KR101312736B1 (ko) * | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| CA2517517C (en) * | 2003-03-03 | 2012-12-18 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2004232973A1 (en) | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| EP1620095A4 (en) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| GB0317471D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
| KR100843526B1 (ko) * | 2004-02-27 | 2008-07-03 | 에프. 호프만-라 로슈 아게 | 피라졸의 접합 유도체 |
| MX2007001126A (es) * | 2004-07-27 | 2007-09-25 | Sgx Pharmaceuticals Inc | Moduladores de heterociclo cinasa de anillo fusionado. |
-
2006
- 2006-11-15 US US11/600,311 patent/US8017781B2/en not_active Expired - Fee Related
- 2006-11-15 AU AU2006315436A patent/AU2006315436A1/en not_active Abandoned
- 2006-11-15 WO PCT/US2006/044361 patent/WO2007059219A1/en not_active Ceased
- 2006-11-15 CA CA002628179A patent/CA2628179A1/en not_active Abandoned
- 2006-11-15 JP JP2008541312A patent/JP2009515984A/ja active Pending
- 2006-11-15 CN CNA2006800507344A patent/CN101365700A/zh active Pending
- 2006-11-15 EP EP06837683A patent/EP1948657A1/en not_active Withdrawn
- 2006-11-15 EP EP11191099A patent/EP2514751A1/en not_active Withdrawn
-
2011
- 2011-07-29 US US13/193,739 patent/US8445681B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2730319C (en) | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | |
| JP2009515984A5 (https=) | ||
| JP2021508686A5 (https=) | ||
| JP6783756B2 (ja) | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン | |
| JP2003525295A5 (https=) | ||
| JP2009513703A5 (https=) | ||
| JP2010513285A5 (https=) | ||
| JP2008526999A5 (https=) | ||
| TW201138772A (en) | Aroylquinoline compounds | |
| JP2009523822A5 (https=) | ||
| JP5129138B2 (ja) | 新規なベンジル（ピリジルメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| US9447103B2 (en) | Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity | |
| CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
| JP2009504771A5 (https=) | ||
| JP2010510216A5 (https=) | ||
| WO2013189266A1 (zh) | 喜树碱类化合物及其制备和用途 | |
| JP6680888B2 (ja) | ピリジノール誘導体またはその薬剤学的に許容可能な塩およびこれを有効成分として含有する薬学組成物 | |
| JP6913955B2 (ja) | ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物 | |
| RU2010124422A (ru) | Производные диоксоантрацен сульфоната | |
| EP0975637B1 (en) | Amidino-camptothecin derivatives | |
| RU2230745C2 (ru) | Оптически чистые аналоги камптотецина | |
| WO2017176981A1 (en) | Small molecule regulators of steroid receptor coactivators and methods of use thereof | |
| JP4791355B2 (ja) | 抗腫瘍活性を有するカンプトテシンの７−イミノ誘導体 | |
| WO2018113758A1 (zh) | 一种作为吲哚胺-2，3-双加氧酶抑制剂的砜脒及其制备方法和用途 | |
| JPH11506111A (ja) | スワインソニンの新規誘導体、それらの調製方法及び治療薬としてのそれらの使用 |